학술논문

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
Document Type
Article
Source
In Annals of Oncology August 2019 30(8):1279-1288
Subject
Language
ISSN
0923-7534